Alaunos Therapeutics, Inc. Common Stock
TCRTStock
$2.07−36.98%52W
Market Cap$5.07M
P/E—
Div yield—
Beta-1.03
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-43.72%
Price vs S&P 500 (4W)-5.51%
VGM Score21.54
Market Capitalization$5.07M
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TCRTAlaunos Therapeutics, Inc. Common Stock | F | F | D | $2.07 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule oral therapies for obesity and metabolic disorders. Its lead program, ALN1001, aims to differentiate itself from GLP-1 receptor agonists by preserving lean muscle mass while treating obesity. The company is evaluating the compound's effects on lipid metabolism and gene expression to establish a competitive profile in the obesity treatment market.